Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela (VENEZUELA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04642339
Recruitment Status : Not yet recruiting
First Posted : November 24, 2020
Last Update Posted : November 24, 2020
Sponsor:
Collaborator:
Ministerio del Poder Popular para la Salud de la República Bolivariana de Venezuela
Information provided by (Responsible Party):
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Brief Summary:
Randomized, double-blind, placebo controlled clinical trial of immunogenicity, safety and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.

Condition or disease Intervention/treatment Phase
Covid19 Biological: Gam-COVID-Vac Biological: Placebo Phase 3

Detailed Description:

Randomized, double-blind (blinded for trial subject and the study physician), placebo controlled clinical trial in parallel assignment of the immunogenicity, safety, and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.

The trial will include 2,000 volunteers over the age of 18. After screening, they will be randomised (3:1) into two groups - a reference group of 500 volunteers who will receive the placebo and a study group of 1,500 volunteers who will receive the combined Gam-COVID-Vac vaccine against SARS-induced coronavirus infection-СoV-2oV-2. The trial subjects will be randomized into five age strata: 18-30, 31-40, 41-50, 51-60 and 60+ years. Each subject will participate in the trial for 180±14 days after the first dose of the study drug/placebo and will have one screening visit and five on-site visits to the study physician during the said period. The study drug/placebo will be administered intramuscularly during vaccination visits 1 and 2 (day 1 and day 21±2). Follow-up visits Nos. 3, 4, 5 will be conducted on days 28±2, 42±2 and 180±14, respectively. Blood samples will be taken from certain subjects during the following visits to assess the immunogenicity parameters on days 1, 42±2 and 180±14. During observation visits, vital indicators will be assessed on all trial subjects and changes in the subjects' condition and well-being will be recorded, observational visits may be remote, using telemedicine (TM) technologies. Additionally, the trial subjects will be able to have remote consultations with the study physician through the TM. Data from trial subjects will be collected through electronic case report forms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Randomized, Double-blind, Placebo Controlled, Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Combined Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: Vaccine Gam-COVID-Vac
Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2 infection
Biological: Gam-COVID-Vac
Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
Other Name: Sputnik V

Placebo Comparator: Placebo
Placebo
Biological: Placebo
Placebo




Primary Outcome Measures :
  1. Seroconversion rate [ Time Frame: 42 day, 180 day ]
    Percentage of trial subjects with fourfold or more increase in the titer of SARS-CoV-2 glycoprotein-specific antibodies in 2,000 trial subjects on the drug administration day before injecting the first dose of the study drug/placebo and 42±2 and 180±14 days after the first dose


Secondary Outcome Measures :
  1. Incidence and severity of adverse events [ Time Frame: through the study (till day 180) ]
    Incidence and severity of adverse events in trial subjects within 6 months after injecting the first dose of the study drug/placebo

  2. Virus-neutralizing antibody levels against the SARS-CoV-2 [ Time Frame: 42 day ]
    Geometric mean virus-neutralizing antibodies titer in 500 trial subjects on the drug administration day before injecting the first dose of the study drug/placebo and 42±2 days after the first dose

  3. Antibody levels against the SARS-CoV-2 glycoprotein [ Time Frame: 42 day, 180 day ]
    Geometric mean titer of the SARS-CoV-2 glycoprotein-specific antibodies in 2,000 trial subjects on the drug administration day before injecting the first dose of the study drug/placebo and 42±2 and 180±14 days after the first dose

  4. Percentage of trial subjects with coronavirus disease 2019 (COVID-19) [ Time Frame: through the study (till day 180) ]
    Percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months, as confirmed with the method of polymerase chain reaction (PCR)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Written informed consent of a subject to participate in the trial
  2. Males and females aged 18+
  3. Negative HIV, hepatitis, and syphilis test results
  4. A negative test result for the presence of IgM and IgG antibodies to SARS CoV2 by enzyme immunoassay
  5. A negative test result for COVID-2019 by PCR at screening visit
  6. No COVID-2019 in the medical history
  7. No contact with COVID-2019 persons within at least 14 days before the enrollment (according to trial subjects)
  8. Consent to use effective contraception methods during the trial
  9. Negative urine pregnancy test at the screening visit (for child-bearing age women)
  10. Negative drugs or psychostimulants urine test at the screening visit
  11. Negative alcohol test at the screening visit
  12. No evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history
  13. No acute infectious and/or respiratory diseases within at least 14 days before the enrollment.

Exclusion Criteria:

  1. Any vaccination/immunization within 30 days before the enrollment;
  2. Steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment.
  3. Immunosuppressors therapy finished within 3 months before the enrollment
  4. Pregnancy or breast-feeding
  5. Acute coronary syndrome or stroke suffered less than one year before the enrollment
  6. Tuberculosis, chronic systemic infections
  7. Drug allergy (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day
  8. Neoplasms in the medical history.
  9. Donated blood or plasma (450+ ml) within 2 months before the enrollment
  10. Splenectomy in the medical history
  11. Neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/L), immunodeficiency in the medical history within 6 months before the enrollment
  12. Active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis B or C
  13. Anorexia, protein deficiency of any origin
  14. Big-size tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the study drug/placebo administration
  15. Alcohol or drug addiction in the medical history
  16. Participation in any other interventional clinical trial.
  17. Any other condition that the study physician considers as a barrier to the trial completion as per the protocol
  18. Study center staff and other employees directly involved in the trial and their families.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04642339


Contacts
Layout table for location contacts
Contact: Alexis H García Piñero, MD +582122191711 alexisgarcia27@gmail.com
Contact: Children's Cardiology Hospital "Dr. Gilberto Rodriguez Ochoa" +582122191711 presidencia@espromedbio.gob.ve

Sponsors and Collaborators
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Ministerio del Poder Popular para la Salud de la República Bolivariana de Venezuela
Investigators
Layout table for investigator information
Principal Investigator: Alexis H García Piñero, MD Children's Cardiology Hospital "Dr. Gilberto Rodriguez Ochoa"
Layout table for additonal information
Responsible Party: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
ClinicalTrials.gov Identifier: NCT04642339    
Other Study ID Numbers: 01V-Gam-COVID-Vac-2020
First Posted: November 24, 2020    Key Record Dates
Last Update Posted: November 24, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation:
vaccine
COVID-19
adenoviral vector
SARS-CoV-2
Ad26
Ad5
Heterologous prime-boost vaccination
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases